ReviewTheranostics2018
Engineered Microenvironments for Maturation of Stem Cell Derived Cardiac Myocytes.
Review in Theranostics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Towards chamber specific heart-on-a-chip for drug testing applications.Advanced drug delivery reviews · 2020Pooled it
- From aging biology to cardiac biotechnology: emerging platforms for modeling cardiac aging.JCI insight · 2026Review
- Engineering Smart Biomaterial Interfaces for iPSC-CM Maturation: A Biophysical and Metabolic Reprogramming Approach to Regenerative Cardiac Medicine.International journal of molecular sciences · 2026Review
- Complementary biomolecular coassemblies direct energy transport for cardiac photostimulators.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Induced Pluripotent Stem Cells in Cardiomyopathy: Advancing Disease Modeling, Therapeutic Development, and Regenerative Therapy.International journal of molecular sciences · 2025Review
- Connexin 43 suppression enhances contractile force in human iPSC-derived cardiac tissues.Frontiers in bioengineering and biotechnology · 2025Article
- Maturation of Human iPSC-Derived Cardiac Microfiber with Electrical Stimulation Device.Advanced healthcare materials · 2024Article
- Comparison of Two Differentiation Protocols of Human-Induced Pluripotent Stem Cells into Cardiomyocytes.Methods in molecular biology (Clifton, N.J.) · 2024Article
- Insights into the pleiotropic roles of ZNF703 in cancer.Heliyon · 2023Review
- Nanoengineering of gold nanoribbon-embedded isogenic stem cell-derived cardiac organoids.RSC advances · 2023Article
- Systematic discovery of transcription factors that improve hPSC-derived cardiomyocyte maturation via temporal analysis of bioengineered cardiac tissues.APL bioengineering · 2023Article
- Maturation of induced pluripotent stem cell-derived cardiomyocytes and its therapeutic effect on myocardial infarction in mouse.Bioactive materials · 2023Article
- Induced pluripotent stem cell-based models: Are we ready for that heart in a dish?Frontiers in cell and developmental biology · 2023Article
- Stem Cell Differentiation into Cardiomyocytes: Current Methods and Emerging Approaches.Stem cell reviews and reports · 2022Review
- An iPS-derived in vitro model of human atrial conduction.Physiological reports · 2022Article
- Modeling hypertrophic cardiomyopathy with human cardiomyocytes derived from induced pluripotent stem cells.Stem cell research & therapy · 2022Review
- The Vascular Niche for Adult Cardiac Progenitor Cells.Antioxidants (Basel, Switzerland) · 2022Review
- Bioengineering approaches to treat the failing heart: from cell biology to 3D printing.Nature reviews. Cardiology · 2022Review
- Intersection of stem cell biology and engineering towards next generationFrontiers in bioengineering and biotechnology · 2022Review
- Bioengineering approaches to mature induced pluripotent stem cell-derived atrial cardiomyocytes to model atrial fibrillation.Experimental biology and medicine (Maywood, N.J.) · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Through the use of stem cell-derived cardiac myocytes, tissue-engineered human myocardial constructs are poised for modeling normal and diseased physiology of the heart, as well as discovery of novel drugs and therapeutic targets in a human relevant manner. This review highlights the recent bioengineering efforts to recapitulate microenvironmental cues to further the maturation state of newly differentiated cardiac myocytes. These techniques include long-term culture, co-culture, exposure to mechanical stimuli, 3D culture, cell-matrix interactions, and electrical stimulation. Each of these methods has produced various degrees of maturation; however, a standardized measure for cardiomyocyte maturation is not yet widely accepted by the scientific community.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.